Daniel E. Geffken - 08 Oct 2021 Form 4 Insider Report for PHOENIX BIOTECH ACQUISITION CORP. (CERO)

Role
Chief Financial Officer
Signature
/s/ Chris Ehrlich, as attorney-in-fact
Issuer symbol
CERO
Transactions as of
08 Oct 2021
Net transactions value
$0
Form type
4
Filing time
12 Oct 2021, 19:35:11 UTC
Previous filing
05 Oct 2021
Next filing
01 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PBAX Class B Common Stock Other +30,000 30,000 08 Oct 2021 Class A Common Stock 30,000 By Phoenix Biotech Sponsor, LLC F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to certain adjustments described in the issuer's charter documents and have no expiration date.
F2 Allocated to the reporting person as a member of Phoenix Biotech Sponsor, LLC.
F3 The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose.